通过PROTAC介导的MDM2的向降解诱导了骨髓瘤细胞中的瘤抑制信号
Yeongji Kim1, Jin-Woo Kim2, Junwon Choi3
1Department of Orthopaedic Surgery, CHA Bundang Medical Center, School of Medicine, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si 13488, Republic of Korea.
Cells
|March 14, 2026
概括
新的蛋白质溶解向嵌合体 (PROTACs) 有效降解MDM2,这是骨髓瘤中关键蛋白质. 这种方法显着有望通过重新激活瘤抑制路径来治疗这种侵袭性骨癌.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 骨髓瘤是年轻人患有预后不佳的常见骨癌.
- MDM2蛋白抑制p53瘤抑制路径,导致癌症的进展.
- 传统的MDM2抑制剂可以通过补偿性MDM2上调导致耐药性.
研究的目的:
- 为了评估针对MDM2的新型PROTAC化合物的抗癌疗效,CL0144和CL0174.4.
- 在骨髓瘤模型中研究这些PROTACs的作用机制.
- 评估针对MDM2的PROTACs在骨髓瘤治疗中的治疗潜力.
主要方法:
- 使用骨髓瘤细胞系 (Saos-2,U2OS) 和体内异种移植模型.
- 服用了针对MDM2的PROTAC化合物CL0144和CL0174.4,这些化合物是针对MDM2的.
- 评估了MDM2降解,p53/p73激活,活性氧物种 (ROS) 生产,细胞亡,细胞活力,增殖,殖民地形成,球体形成,迁移和入侵.
主要成果:
- 这两种PROTAC都有效地诱导了骨髓瘤细胞中的MDM2降解.
- PROTAC治疗激活了p53/p73信号传递,增加了ROS,诱导了细胞亡,并降低了细胞活力.
- 观察到大量抑制扩散,殖民地形成,球体形成,迁移和入侵.
- 在体内研究显示,骨髓瘤瘤生长的强有力的抑制.
结论:
- 向MDM2的PROTACs在骨髓瘤中表现出强大的抗癌活性.
- 这些PROTACs通过降解MDM2和破坏瘤信号通路而起作用.
- 向MDM2的PROTACs是骨髓瘤的一个有前途的治疗策略.
相关概念视频
Abnormal Proliferation
5.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
mTOR Signaling and Cancer Progression
5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.0K
PI3K/mTOR/AKT Signaling Pathway
6.1K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
6.1K
Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
Loss of Tumor Suppressor Gene Functions
6.2K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
6.2K


